Q-omics provides the consensus-scored MAMDC4 profile across patient tissues and cancer cell-line models. MAMDC4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAMDC4 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, MAMDC4 RNA expression shows 18,443 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where MAMDC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAMDC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAMDC4 survival associations across molecular data types. MAMDC4 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAMDC4 RNA expression–survival associations across cancer types. High MAMDC4 expression shows unfavorable associations in KIRC, PRAD and COAD, but favorable associations in HNSC, PAAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAMDC4 RNA expression.
This table summarizes MAMDC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MAMDC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAMDC4 shows higher tumor expression in KIRC, STAD, BLCA, UCEC, COAD and READ. The KIRC box plot shows higher MAMDC4 RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with MAMDC4 in patient tissues and cancer cell lines. In patient samples, MAMDC4 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MAMDC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
